digiMedical Solutions, Inc.(TM) Appoints Jason Whisenant to Advisory Board to Focus on High Margin Digital Prescriptions Software Sales

COLLEYVILLE, TX--(Marketwire - April 14, 2009) - digiMedical Solutions, Inc. ™ (PINKSHEETS: DGMS) today announced the Company has appointed Jason Whisenant to its Advisory Board. Mr. Whisenant will focus on the Company's sales and marketing strategies, primarily as they relate to private labeling and strategic partnerships. Since last year, the Company has repositioned to focus on a high margin software revenue model, selling its proprietary digital prescription software to both clinics and pharmacies. Recently, the Company has also announced developing relationships with other companies to allow them to private label the Company's software in an effort to quickly increase digiMedical sales channels and associated transaction revenue.

Mr. Whisenant has over 15 years' experience in both strategic marketing and sales advisory roles. After studying at the University of Arkansas at Little Rock (UALR), Mr. Whisenant founded and operated seven retail chain stores, which were eventually sold as he began consulting small to medium companies on how to achieve marketing goals. Mr. Whisenant is currently employed by a NASDAQ-listed corporation in which Mr. Whisenant is architecting new lines of business.

David Lee, digiMedical CEO, stated, "With Mr. Whisenant's robust retail, supply management and E-commerce experience, I know he will be able to provide incredible insight into how we can approach our new software model. One of Mr. Whisenant's first suggestions was to private label our products, a process which we have already begun. We are excited Mr. Whisenant has accepted this role, and we look forward to his input as we continue to make progress toward new ventures."

Jason Whisenant commented, "Mr. Lee and I have known each other almost 20 years, and I know the character and the determination he brings to digiMedical. I am excited to advise both Mr. Lee and digiMedical as the Company navigates the ever changing world of sales and marketing. It will take lots of energy and fortitude to move the Company's proven products into an E-commerce and private label market, nevertheless after visiting with the key management of the Company, I know we will be successful."

Separately, the Company recently launched a new interactive corporate website. The new site, www.digimedical.com, offers doctors, patients, pharmacists and investors a clear view of the company's technology, service offerings and current news and events. Utilizing the latest Microsoft technologies such as .NET, AJAX and Microsoft SQL, the Company has developed a suite of products to digitally manage the prescription process. The company's products comply with all HIPAA and DEA requirements for patient medical record security.

To be added to digiMedical's corporate e-mail list to receive company updates, please send an e-mail to ir@digimedical.com.

About digiMedical Solutions, Inc.™ (www.digiMedical.com)

digiMedical Solutions, Inc.™ is a pharmacy and medical technology company focused on developing next generation, digital medical technology with an emphasis on digital prescriptions (d-Prescriptions) that closely align the doctor, pharmacist and patient. The company's planned growth will come from three channels: direct marketing of the company's wireless based d-prescription technology to physicians, direct marketing of the company's digital call center services for refills and reauthorization and partnering with independent pharmacy chains to focus sales with the technology suite.

Forward-Looking Statement

Statements included in this press release which are not historical in nature, are intended to be, and are hereby identified as "Forward-Looking Statements" for purposes of safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended. Forward-Looking Statements may be identified by words including "anticipate," "await," "envision," "foresee," "aim at," "believe," "intends," "estimates" including without limitation, those relating to the company's future business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the Forward-Looking Statements. Readers are directed to the company's filings with the U.S. Securities and Exchange Commission.

Contact Information: Contact: digiMedical Solutions, Inc. Investor Relations 214-722-3029 ir@digimedical.com www.digimedical.com